Lixte Biotechnology Holdings Inc ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Lixte Biotechnology Holdings Inc zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Lixte Biotechnology Holdings Inc zu Deinem Portfolio hinzuzufügen.
BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight shifts to the science itself.
BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT) had other plans.
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions.
-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Compa...
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre
DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Ca...
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.